HU-433

HU-433 is a synthetic **small molecule cannabinoid** developed by researchers at **Hebrew University of Jerusalem**. It is the enantiomer of HU-308 and functions as a **highly selective agonist of the cannabinoid receptor type 2**, with reported lack of meaningful binding to cannabinoid receptor type 1. In preclinical systems, HU-433 showed markedly greater potency than HU-308 in osteoblast proliferation, osteoclast differentiation, rescue of ovariectomy-induced bone loss, and anti-inflammatory models such as ear inflammation, supporting its investigation as a potential **antiosteoporotic and anti-inflammatory** therapeutic. The compound appears to be a research-stage agent rather than a clinically developed pharmaceutical product.